Responses to parliamentary questions
Question from Deputy John Clendennen - PQ 21310-26
Deputy Clendennen asked for an update on the accessibility of the drug Givinostat (brand name Duvyzat) for the treatment of Duchenne muscular dystrophy.
From: Communications and public affairs
Published: March 2026
Updated: April 2026
Documents
Question from Deputy John Clendennen - PQ 21310-26
PDF, 736KB, 3 pages
Summary
To ask the Minister for Health for an update on the accessibility of the drug Givinostat (brand name Duvyzat) for the treatment of Duchenne muscular dystrophy, given the outcome of the NCPE assessment as of 3 March 2026; and if she will make a statement on the matter.
This is a beta version - your feedback will help us to improve it